Lonza enters a collaborative agreement with Auxly for capsule formulation
Through this agreement, Auxly’s wholly-owned subsidiary Dosecann will receive a complete line of equipment needed for capsule filling and sealing, alongside with Lonza’s Capsugel LEMS machine – its proprietary liquid-filled Licaps capsules, and rights to the capsule filling and sealing LEMS technology.
Additionally, Dosecann and Lonza will work on new product formulation for cannabis capsule products as part of the agreement.
Lonza’s Capsugel technology is currently used in health applications for bioavailability enhancement, taste and odor masking, combination products, and controlled and delayed release formulations.
Greg Boone, CEO of Dosecann, told us that the use of formulated capsules has the potential to gain a large share in the medical market, as people are familiar with dosage forms.
Boone added that Dosecann has begun formulation for capsules and has just completed its first batch of capsules utilizing the Capsugel equipment.
Through this agreement, Doescann will be commissioning the LEMS technology at its good manufacturing practice (GMP) compliant facility in Charlottesville, Canada.
The facility will have a full manufacturing line with the capacity to fill and seal up to 200 million Capsugel Licaps per year.
